Niagen Bioscience, Inc. (NAGE) Stock Price, News, Quote & History
Niagen Bioscience, Inc. (NAGE) stock closed at $2.68, down 8.22%, with after-hours trading showing a slight increase. The company, formerly ChromaDex Corporation, focuses on healthy aging products, including its proprietary ingredient Niagen. Key financial data includes a market cap of $213.447M, a P/E ratio of 14.11, and a 1-year target estimate of $12.08, despite significant year-to-date and 1-year stock price declines.
Niagen Bioscience, Inc. (NAGE) stock price, news, quote and history
This article provides detailed financial information for Niagen Bioscience, Inc. (NAGE), including its current stock price, recent performance, key financial metrics, and historical data. It lists real-time trading data, market capitalization, volume, and various valuation measures. The page also includes links to recent news and related stocks.
Niagen Bioscience appoints Dr. Abhijit Kale to lead global research
Niagen Bioscience has appointed Dr. Abhijit Kale as Senior Director of Global External Research, effective July 20, 2026. Dr. Kale will head the Global Niagen Research Program, which currently supports over 175 studies and collaborates with major institutions. Under his leadership, the company aims to expand its research into pharmaceutical-grade applications and explore other NAD+ precursors.
Niagen Bioscience signs agreement for clinical trial planning
Niagen Bioscience Inc. (NASDAQ:NAGE) has signed a Start-Up Agreement with Mass General Brigham to plan a multi-year clinical trial. The trial will evaluate the effects of nicotinamide riboside supplementation in adults aged 50 and older on major clinical outcomes and healthy aging-related measures. This collaboration aims to understand how nutritional interventions impact clinically meaningful outcomes over time, with final design elements still subject to planning and agreements.
Niagen Bioscience to present at Canaccord Genuity’s 46th Annual Growth Conference
Niagen Bioscience (NASDAQ: NAGE) will present at Canaccord Genuity's 46th Annual Growth Conference in Boston from August 11-13, 2026. CEO Rob Fried and CFO Ozan Pamir will engage with investors, highlighting the company's leadership in NAD+ science and healthy aging. Rob Fried will host a fireside chat on August 11 at 2:00 p.m. ET, and one-on-one meetings will be held with institutional investors.
Transcript: Niagen Bioscience Q2 2026 Earnings Conference Call
Niagen Bioscience reported Q2 2026 revenue of $29.8 million, with Tru Niagen sales up 6% year-over-year, driven by a 14% increase in e-commerce. The company is expanding beyond supplements into skincare and pharmaceuticals, launching NAD Pharmaceuticals and developing NB4168 for rare genetic diseases, and is also targeting the IV and injection markets with Niagen Plus. Management highlighted the resilience of its core business and expressed confidence in multiple long-term growth engines while maintaining financial discipline and a strong balance sheet.
Niagen Bioscience: Down 68%, But Still Not Quite A Buy (NASDAQ:NAGE)
Niagen Bioscience (NAGE) is assigned a "hold" rating due to strong fundamentals and a debt-free balance sheet being offset by limited valuation upside. A DCF analysis estimates the intrinsic value at $2.66 per share, indicating the stock is currently trading above its fair value. While Tru Niagen and e-commerce show growth, weaker ingredient sales and increased spending pressured profitability in Q2.
Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Average Recommendation of "Buy" by Analysts
Niagen Bioscience, Inc. (NASDAQ:NAGE) has received an average "Buy" recommendation from analysts, with a 12-month price target of $10.33. Despite recent stock declines, opening at $3.00 near its 12-month low, the company met adjusted earnings per share expectations in its last quarterly report. Institutional investors hold a significant 15.41% stake in the bioscience firm, which specializes in products supporting healthy aging and cellular energy metabolism.
Older mothers’ placentas had less NAD+, a cell-energy molecule. Restoring it improved pregnancy outcomes in aged mice.
A new preclinical study published in Nature Communications suggests that the CD38 enzyme drives age-related NAD+ decline in placental tissue, leading to poorer pregnancy outcomes in older mothers. The research indicates that restoring NAD+ levels with nicotinamide riboside (NR) improved placental, fetal, and offspring outcomes in aged mice, and highlights that NR may be more effective than NMN in tissues with high CD38 activity. Niagen Bioscience, while not funding the study, emphasizes its importance in understanding NAD+ decline and the role of different NAD+ precursors.
Niagen Bioscience engages advisors for drug development strategy By Investing.com
Niagen Bioscience's subsidiary, NAD Pharmaceuticals Corp., has hired Red Sky Partners and Martin Hendrix, Ph.D., as strategic advisors to bolster the development of NB4168 and facilitate corporate growth. The advisors will provide expertise in advancing NB4168, an investigational drug for rare genetic diseases and aging-related disorders, and assist with corporate strategy, business development, and potential M&A initiatives. NB4168 is focused on treating Ataxia Telangiectasia, a condition currently without FDA-approved therapies.
Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
Niagen Bioscience has engaged Red Sky Partners and Martin Hendrix, Ph.D., to bolster its drug development program and strategic corporate growth initiatives. These advisors bring extensive experience in biotechnology fundraising, drug development, commercialization, corporate strategy, and M&A, particularly to support the advancement of NB4168, an investigational drug for rare genetic diseases and aging-related disorders. The company aims to leverage their expertise to translate its NAD+ leadership into long-term value and expand its pharmaceutical strategy for unmet medical needs, such as Ataxia Telangiectasia.
Niagen Bioscience engages advisors for drug development strategy By Investing.com
Niagen Bioscience's subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners and Martin Hendrix, Ph.D., as strategic advisors to advance its investigational drug candidate, NB4168, and support corporate growth. NB4168 targets rare genetic diseases and aging-related disorders, with an initial focus on Ataxia Telangiectasia. The advisors bring extensive experience in biotechnology, business development, and mergers and acquisitions.
Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
Niagen Bioscience has engaged Red Sky Partners and Martin Hendrix, Ph.D., as strategic advisors to bolster its drug development program and corporate growth. Red Sky Partners will focus on advancing NB4168, an investigational drug for rare genetic diseases, while Dr. Hendrix will advise on broader corporate strategy, business development, and M&A. This move aims to leverage their extensive experience in biopharmaceutical development, strategic transactions, and commercialization to drive the company's next phase of growth.
Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
Niagen Bioscience, a company specializing in NAD+ science and healthy aging, announced its participation in the Nasdaq X LD Micro Inaugural SF Summit. CFO Ozan Pamir will present the company's advancements and engage with institutional investors at the event, which features 25 curated public companies. The company is known for its Niagen® product, a patented NAD+ booster, and its focus on advancing healthspan through scientific research.
Niagen Bioscience stock gains GNC, Sam’s Club distribution, Canaccord reiterates buy
Niagen Bioscience (NASDAQ:NAGE) has announced expanded retail distribution for its Tru Niagen NAD+ supplement, now available at GNC and Sam’s Club stores. Canaccord Genuity reiterated a Buy rating and a $10.00 price target, citing the expanded distribution and the company's innovation pipeline. The company is also making strides in rare genetic disease treatments with its subsidiary NAD Pharmaceuticals Corp.
Niagen Bioscience stock gains GNC, Sam’s Club distribution, Canaccord reiterates buy
Niagen Bioscience (NASDAQ:NAGE) has expanded its retail distribution for its Tru Niagen NAD+ supplement to GNC and Sam’s Club, prompting Canaccord Genuity to reiterate a Buy rating and a $10.00 price target. This expansion is expected to boost sales, alongside the company's innovation pipeline and recent advancements in drug development for rare genetic diseases, such as NB4168 which received Rare Pediatric Disease Designation from the FDA. Despite a recent stock decline, analysis suggests the stock is undervalued with strong gross profit margins.
Niagen Bioscience lists Tru Niagen supplement on Walmart.com
Niagen Bioscience announced that its Tru Niagen NAD+ supplement is now available on Walmart.com, starting with 300 mg in 30-count and 90-count bottles, with plans for further expansion. CEO Rob Fried stated this move increases accessibility for their "science-backed NAD+ solution." The company highlights Tru Niagen's clinical backing and market position as the leading NAD+ boosting oral supplement in the U.S.
Niagen Bioscience Leads The Way With 2 Promising Penny Stocks
This article highlights several penny stocks with strong financial foundations and growth potential, despite the U.S. market's recent dip. It focuses on Niagen Bioscience (NAGE), Nutriband (NTRB), and Definitive Healthcare (DH), detailing their market caps, operational revenues, recent financial performance, and strategic positioning within their respective industries. The analysis aims to identify promising opportunities for investors interested in smaller, high-growth companies.
Niagen Bioscience Leads The Way With 2 Promising Penny Stocks
This article highlights two penny stocks, Niagen Bioscience (NAGE) and Nutriband (NTRB), that show promise despite the inherent volatility of smaller companies. Niagen Bioscience, with a market cap of US$251.36 million, is expanding its healthy aging products and maintains a debt-free balance sheet. Nutriband, valued at US$43.15 million, is developing transdermal pharmaceutical products and has strengthened its financial position with a new credit line.
Supplement Retail Expansions
Niagen Bioscience has expanded the retail availability of its Tru Niagen product line, including Tru Niagen Beauty, into GNC and Sam's Club stores across 44 states. This move signifies a broader trend of science-backed healthy aging supplements transitioning from niche wellness shops to mainstream retail, making advanced cellular health products more accessible to everyday consumers. The expansion highlights growing consumer interest in NAD+ support for cellular energy, mitochondrial function, and DNA repair, as well as the increasing market for beauty-from-within ingestible supplements.
Niagen Bioscience expands Tru Niagen to GNC, Sam’s Club stores
Niagen Bioscience (NASDAQ:NAGE) announced that its Tru Niagen supplement is now available at GNC and Sam’s Club retail locations and online, significantly expanding its retail footprint to nearly 300 stores across 44 states. The expansion includes different product sizes and formulations for each retailer. Tru Niagen is an NAD+ boosting supplement backed by extensive clinical studies.
Niagen Bioscience (Nasdaq:NAGE) - Aktienanalyse
Niagen Bioscience (Nasdaq:NAGE) is a biotech company focused on healthy aging products, currently trading at US$3.21 with a market capitalization of US$254.5 million. The stock has seen significant volatility, with a 68% drop over the last year, despite recent positive news regarding its drug development program, NB4168, which received Rare Pediatric Disease and Orphan Medicinal Product Designations for Ataxia Telangiectasia. The company has also expanded its product lines, including a telehealth platform and skincare, and recently reported strong Q1 2026 earnings that exceeded analyst expectations.
Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club
Niagen Bioscience has expanded the retail availability of its Tru Niagen® supplement, now offering it at GNC and Sam's Club stores and online. This move strengthens the company's retail presence and makes the NAD-boosting healthy-aging supplement accessible to a broader consumer base across 44 states. Tru Niagen® is supported by extensive clinical studies and patents, affirming its scientific backing and quality standards.
Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club
Niagen Bioscience announced that its Tru Niagen® healthy aging supplement is now available at nearly 300 GNC and Sam’s Club locations across 44 states and online. This expansion includes Tru Niagen Beauty at GNC and various Tru Niagen 300mg bottle counts at both retailers, significantly strengthening its retail presence. The move reflects growing consumer demand for science-backed healthy aging solutions, leveraging Tru Niagen's clinically proven NAD+ boosting capabilities.
Tieton Capital Management LLC Purchases New Position in Niagen Bioscience, Inc. $NAGE
Tieton Capital Management LLC has acquired a new position in Niagen Bioscience, Inc. (NASDAQ:NAGE), purchasing over 2 million shares valued at approximately $6.4 million, representing 1.8% of their investment portfolio. Other institutional investors have also recently bought into Niagen Bioscience, with hedge funds and institutional investors collectively owning 15.41% of the company's stock. Analysts generally maintain a "Buy" rating for NAGE, with a consensus price target of $10.33, despite the stock trading significantly below its 52-week high.
Niagen Bioscience CFO Presentation in Chicago Will Be Livestreamed
Niagen Bioscience (NASDAQ: NAGE) announced that its CFO, Ozan Pamir, will present at the Midwest IDEAS Investor Conference on Thursday, August 27, 2026, in Chicago. The presentation, focusing on the company's investment merits and NAD+ science, will be livestreamed. Niagen Bioscience, a global authority on NAD+, is dedicated to advancing healthspan through its innovative NAD+-boosting solutions, including its consumer supplement Tru Niagen® and pharmaceutical-grade Niagen™ Plus.
Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
Niagen Bioscience has launched its leading healthy-aging NAD+ supplement, Tru Niagen, on Walmart.com, significantly expanding its e-commerce reach and consumer access. This move allows more consumers nationwide to purchase the clinically proven supplement, which is backed by extensive scientific research and helps support cellular function and healthy aging. The initial rollout includes 300 mg bottles, with more products to follow, capitalizing on Walmart's growing digital platform and health and wellness sales.
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
Niagen Bioscience has partnered with Evotec to advance the preclinical development of NB4168, their lead investigational candidate for rare pediatric diseases, particularly Ataxia Telangiectasia (A-T). Evotec will conduct pharmacokinetic, pharmacodynamic, and bioanalytical studies at their Verona campus, utilizing their INDiGO platform to accelerate the development process. NB4168 is a proprietary oral small-molecule designed to increase NR exposure, supporting NAD+ pathways that are disrupted in A-T, and has received Rare Pediatric Disease and Orphan Medicinal Product Designations.
Niagen Bioscience launches Tru Niagen on Walmart.com
Niagen Bioscience has launched its Tru Niagen NAD+ supplement on Walmart.com, making its healthy-aging product more widely available. The initial offering includes 300 mg bottles, with more products to follow. Tru Niagen, which contains patented nicotinamide riboside, is backed by numerous human clinical studies and is cited as the top-selling NAD+ supplement in the U.S. e-commerce market.
Sei Investments Co. Increases Holdings in Niagen Bioscience, Inc. $NAGE
Sei Investments Co. significantly increased its stake in Niagen Bioscience, Inc. (NASDAQ:NAGE) by 155.6% in the first quarter, now owning 971,574 shares valued at $4.29 million. Despite this increased institutional interest, Niagen Bioscience shares opened down 14.7% near their 52-week low, with quarterly earnings matching expectations but revenue falling slightly short. Analysts maintain a generally positive outlook with an average "Buy" rating and a consensus price target of $10.33.
Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
Niagen Bioscience has launched its Tru Niagen supplement on Walmart.com, significantly broadening consumer access to its leading healthy-aging NAD+ product. This move diversifies Niagen Bioscience's e-commerce presence, leveraging Walmart's substantial digital reach and health and wellness market share. The initial offering includes 300 mg Tru Niagen in 30-count and 90-count bottles, with more products to follow, aiming to meet consumers where they shop.
Q2 2026 Niagen Bioscience Inc Earnings Call Transcript
This document provides the earnings call transcript for Niagen Bioscience Inc.'s (NAGE) second quarter of 2026. Key points highlight strong e-commerce growth, expansion into new verticals like skincare and IV/injection, a robust balance sheet, and progress in its pharmaceutical pipeline. However, the report also notes negative aspects such as lower ingredient business revenue, increased selling and marketing expenses, and a decline in net income.
Niagen Bioscience, Inc. Stock 12‑Month Price Target Cut to $12.08, Implies 248% Upside
Niagen Bioscience, Inc.'s average stock price target has been reduced slightly from $12.42 to $12.08 by 6 analysts, with forecasts ranging from $8.5 to $22 per share. Despite the cut, the updated target suggests a 248% potential upside based on the August 4th closing price. The consensus rating for the stock remains a "Buy" from all 6 covering analysts.
Niagen Bioscience (NAGE) On New Aging Study And The Case For A Higher Fair Value
Niagen Bioscience (NAGE) is gaining attention after a new study linked its Niagen nicotinamide riboside supplementation to reduced muscle epigenetic age acceleration. Despite recent stock price declines, the company's valuation is seen as undervalued at $2.96 compared to a fair value of $12.60, driven by anticipated growth in pharmaceutical-grade Niagen and e-commerce. However, risks related to regulatory outcomes and potential pressure on margins remain.
CCORF Maintains Niagen Bioscience(NAGE.US) With Buy Rating, Maintains Target Price $10
CCORF has reiterated its Buy rating for Niagen Bioscience (NAGE.US) and maintained its target price at $10. This indicates a continued positive outlook from the firm regarding Niagen Bioscience's stock performance.
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
Niagen Bioscience, Inc. announced its Q2 2026 financial results, reporting net sales of $29.8 million and a net income of $1.0 million. The company also highlighted strategic advancements, including the launch of its Niagen Plus telehealth platform and the introduction of NB4168, a pharmaceutical candidate for rare genetic and aging-related diseases. Niagen Bioscience is transitioning into a multi-asset anti-aging company, leveraging its consumer business to fund new growth initiatives.
Niagen Bioscience Inc (NAGE) (Q2 2026) Earnings Call Highlights: E-Commerce Surge and China ...
Niagen Bioscience Inc (NAGE) reported robust Q2 2026 results, driven by significant e-commerce growth, particularly on its TrueNiagen website and Amazon, and impressive expansion in the China cross-border market. The company is strategically diversifying into new high-growth verticals like skincare and IV/injection therapies, backed by a strong balance sheet and advancements in its pharmaceutical pipeline. Despite facing challenges such as increased marketing expenses, declining net income, and competitive pressures in its ingredient business, NAGE remains focused on long-term growth and shareholder value, with ongoing legal battles, retail expansions, and pharma developments outlined during the earnings call.
Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Consensus Rating of "Buy" by Brokerages
Niagen Bioscience, Inc. (NASDAQ:NAGE) has received a consensus "Buy" rating from five brokerages, with an average 12-month price target of $10.33. Despite the positive analyst sentiment, the company's shares recently traded down to $3.06, near its 52-week low. Institutional investors hold a significant 15.41% stake in the company, which reported quarterly EPS of $0.01, meeting estimates, and revenue slightly below forecasts.
Earnings call transcript: Niagen Bioscience posts q2 2026 growth, lifts spending
Niagen Bioscience (CDXC) reported Q2 2026 revenue of $29.8 million, driven by growth in its Tru Niagen supplement and e-commerce, but net income dropped to $1 million ($0.01 per diluted share) due to increased marketing and product development spending. The company is transitioning into a broader "NAD platform company" with ventures into consumer health, injectable/IV products, skincare, and pharmaceuticals. Management views 2026 as an investment year, anticipating future growth from these new initiatives while maintaining a strong balance sheet.
Niagen Bioscience (NASDAQ:NAGE) Announces Quarterly Earnings Results, Meets Expectations
Niagen Bioscience (NASDAQ:NAGE) reported quarterly earnings of $0.01 EPS, which met analyst expectations. The company demonstrated a net margin of 14.29% and a return on equity of 22.68%. Despite the stock trading near its 52-week low, analysts maintain a generally positive "Buy" rating with an average price target of $10.50.
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
Niagen Bioscience, Inc. announced its Q2 2026 financial results, reporting net sales of $29.8 million and a net income of $1.0 million. The company highlighted the launch of its Niagen Plus telehealth platform and the pharmaceutical program targeting rare genetic diseases with its investigational therapeutic candidate, NB4168. Niagen Bioscience also provided a 2026 outlook, forecasting 10% to 15% growth for its e-commerce business and strategic investments in its pharmaceutical and telehealth initiatives.
Niagen Bioscience (NAGE) FDA Approvals, PDUFA Dates & Drug Alerts 2026
Niagen Bioscience (NAGE) is advancing its drug candidate NB4168 for the treatment of Ataxia Telangiectasia. The company recently announced that it has selected Evotec as a contract research organization to support NB4168's development and previously received Rare Pediatric Disease designation from the FDA for this drug. While NB4168 is undergoing regulatory review, Niagen Bioscience has not yet received any FDA approvals for its therapies in the last two years.
Niagen Bioscience selects Evotec for rare disease drug studies
Niagen Bioscience has partnered with Evotec to support the development of NB4168, an oral small-molecule candidate for Ataxia Telangiectasia (A-T), a rare pediatric genetic disease. Evotec will conduct pharmacokinetic and pharmacodynamic studies and validate bioanalytical methods for NB4168. Niagen Bioscience plans to submit an Investigational New Drug application to the FDA for human clinical studies of NB4168, which has already received Rare Pediatric Disease and Orphan Medicinal Product designations.
Evotec to Study NB4168 for Rare Pediatric Disease With No Approved Treatment
Niagen Bioscience has partnered with Evotec, a global life science company, to advance the preclinical development of NB4168, a proprietary oral small-molecule candidate for Ataxia Telangiectasia (A-T), a rare pediatric genetic disease with no approved treatments. Evotec will conduct pharmacokinetic, pharmacodynamic, and bioanalytical studies at its Verona campus, utilizing its INDiGO platform to streamline the path to clinical evaluation. This collaboration aims to generate the necessary pharmacological and bioanalytical evidence to progress NB4168 toward human clinical studies, supported by its existing Rare Pediatric Disease and Orphan Medicinal Product Designations.
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
Niagen Bioscience has partnered with Evotec to advance the preclinical development of NB4168, their lead investigational candidate for rare pediatric diseases like Ataxia Telangiectasia (A-T). Evotec will conduct pharmacokinetic, pharmacodynamic, and bioanalytical studies at their Verona campus, leveraging their INDiGO platform to streamline development. This collaboration aims to generate crucial data to support Niagen Bioscience's Investigational New Drug (IND) application for NB4168, which has already received Rare Pediatric Disease Designation from the FDA and Orphan Medicinal Product Designation from the EMA.
Arrowstreet Capital Limited Partnership Buys 761,685 Shares of Niagen Bioscience, Inc. $NAGE
Arrowstreet Capital Limited Partnership significantly increased its stake in Niagen Bioscience, Inc. (NASDAQ:NAGE) by purchasing 761,685 additional shares in the first quarter, bringing its total holdings to 2,378,437 shares valued at $10.489 million. Other institutional investors like JPMorgan Chase & Co., SteelPeak Wealth LLC, and UBS Group AG also modified their positions. The article also provides Niagen Bioscience's recent price performance, earnings data, and analyst ratings, which show a consensus "Buy" rating with an average price target of $10.50.
Niagen Bioscience Inc (NAGE) Institutional Confidence
Niagen Bioscience Inc (NAGE) has an institutional shareholding score of 3.00, placing it 191st out of 384 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 38.95%, reflecting a 23.33% decrease quarter-over-quarter. James Simons is the largest institutional shareholder with 1.67% of shares outstanding.
Niagen Bioscience, Inc. Revenue Breakdown – DUS:OCD1
Niagen Bioscience, Inc. (OCD1) generated €110.19 million in revenue last year. The Consumer Products segment was the top performer, contributing €83.16 million, and the United States was the largest regional contributor, accounting for €86.50 million in revenue.
Niagen Bioscience reports study on muscle aging markers By Investing.com
Niagen Bioscience Inc. announced the publication of a peer-reviewed analysis in Aging Cell, which found that Niagen nicotinamide riboside supplementation for five months was associated with reducing muscle epigenetic age acceleration by approximately 2.5 years. The study involved analyzing skeletal muscle and blood samples from three previous clinical trials, with six out of seven epigenetic clocks showing changes consistent with lower epigenetic age acceleration. The company notes that these findings are preliminary, stemming from a secondary analysis of previously conducted studies.
NAGE|Niagen Bioscience Inc|Price:3.270|Chg%:+0.040
Niagen Bioscience Inc (NAGE) is rated "Buy" by multiple analysts with a target price of $12.50, indicating a significant upside potential of 289.41%. The company has strong fundamentals, including 3-year average revenue growth of 54.87%, and an undervaluation with a P/E of 13.83. Despite positive analyst sentiment and growth, the stock is expected to trend down in the medium term, currently trading sideways, and is considered fairly valued within its industry.
